JP2024538707A - Ｉｌ－２プロドラッグ - Google Patents

Ｉｌ－２プロドラッグ Download PDF

Info

Publication number
JP2024538707A
JP2024538707A JP2024520927A JP2024520927A JP2024538707A JP 2024538707 A JP2024538707 A JP 2024538707A JP 2024520927 A JP2024520927 A JP 2024520927A JP 2024520927 A JP2024520927 A JP 2024520927A JP 2024538707 A JP2024538707 A JP 2024538707A
Authority
JP
Japan
Prior art keywords
tumor
prodrug
inducible
compound
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520927A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023060242A5 (https=
JP2024538707A5 (https=
Inventor
ホセ アンドレス サルメロン－ガルシア，
ウィリアム ウィンストン，
ダニエル ヒックリン，
シンシア サイデル－デュガン，
ヘザー ブロドキン，
クリストファー ニルシュル，
ティツィアーナ カファレリ，
Original Assignee
ウェアウルフ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェアウルフ セラピューティクス， インコーポレイテッド filed Critical ウェアウルフ セラピューティクス， インコーポレイテッド
Publication of JP2024538707A publication Critical patent/JP2024538707A/ja
Publication of JPWO2023060242A5 publication Critical patent/JPWO2023060242A5/ja
Publication of JP2024538707A5 publication Critical patent/JP2024538707A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024520927A 2021-10-08 2022-10-07 Ｉｌ－２プロドラッグ Pending JP2024538707A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163253964P 2021-10-08 2021-10-08
US63/253,964 2021-10-08
US202163290941P 2021-12-17 2021-12-17
US63/290,941 2021-12-17
US202263328524P 2022-04-07 2022-04-07
US63/328,524 2022-04-07
PCT/US2022/077772 WO2023060242A1 (en) 2021-10-08 2022-10-07 Il-2 prodrug

Publications (3)

Publication Number Publication Date
JP2024538707A true JP2024538707A (ja) 2024-10-23
JPWO2023060242A5 JPWO2023060242A5 (https=) 2025-09-24
JP2024538707A5 JP2024538707A5 (https=) 2025-09-24

Family

ID=83978868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520927A Pending JP2024538707A (ja) 2021-10-08 2022-10-07 Ｉｌ－２プロドラッグ

Country Status (6)

Country Link
US (1) US20240374687A1 (https=)
EP (1) EP4412712A1 (https=)
JP (1) JP2024538707A (https=)
KR (1) KR20240082401A (https=)
CA (1) CA3233893A1 (https=)
WO (1) WO2023060242A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250977A1 (en) * 2024-05-31 2025-12-04 Werewolf Therapeutics, Inc. Cancer therapy using il-2 prodrug
WO2026072455A1 (en) * 2024-09-26 2026-04-02 Werewolf Therapeutics, Inc. Single domain human serum albumin antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes

Also Published As

Publication number Publication date
CA3233893A1 (en) 2023-04-13
EP4412712A1 (en) 2024-08-14
WO2023060242A1 (en) 2023-04-13
US20240374687A1 (en) 2024-11-14
KR20240082401A (ko) 2024-06-10

Similar Documents

Publication Publication Date Title
Zhang et al. Low-dose IL-2 therapy in autoimmune diseases: An update review
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
CN110831961B (zh) 用于免疫疗法的cd19组合物和方法
Nirschl et al. Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression
US20230019085A1 (en) Psgl-1 modulators and uses thereof
TW202016139A (zh) Bcma 嵌合抗原受體及其用途
JP2015508816A (ja) Ｏｘ４０アゴニスト／ｉｌ−２二重癌治療法
US20240010976A1 (en) Methods and compositions for stimulating gamma delta t cells
US20240374687A1 (en) Il-2 prodrug
TW201716072A (zh) 治療腹膜癌之組成物和方法
KR20230010228A (ko) 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
JP2023505925A (ja) バリアント型インターロイキン－２（ｖＩＬ－２）ポリペプチドをコードする腫瘍溶解性ウイルスベクター
CN119816313A (zh) 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
Zhang et al. Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights
Ahn et al. Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity
CN118027212A (zh) Il-15与t细胞共刺激分子抗体构成的双功能融合蛋白
CN117813320A (zh) 嵌合蛋白和免疫治疗方法
US11866493B2 (en) Single-chain variable fragment of Met monoclonal antibody and methods of use in CAR T cell therapy
Czyżewski et al. CAR-T cell therapy for glioblastoma: advances, challenges, and future directions
KR20240099228A (ko) 조작된 nk 세포 및 이의 용도
Montorfani et al. Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies
KR20230096049A (ko) 편평 세포 암종 치료용 IL-2/IL-15Rβγ 작용제
RU2775490C2 (ru) Химерные белки на основе tigit и light
Nirschl et al. Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression
Zeng et al. Cis-delivering releasable IL-15 superagonist enhances antitumor immunity in cold tumors by invigorating preexisting CD25+ CD8+ T cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250912